Logo image of VNDA

VANDA PHARMACEUTICALS INC (VNDA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VNDA - US9216591084 - Common Stock

6.75 USD
+0.08 (+1.2%)
Last: 12/19/2025, 8:20:43 PM
6.82 USD
+0.07 (+1.04%)
After Hours: 12/19/2025, 8:20:43 PM
Fundamental Rating

2

VNDA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. While VNDA is still in line with the averages on profitability rating, there are concerns on its financial health. VNDA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

VNDA had negative earnings in the past year.
In the past year VNDA has reported a negative cash flow from operations.
Of the past 5 years VNDA 4 years were profitable.
VNDA had a positive operating cash flow in 4 of the past 5 years.
VNDA Yearly Net Income VS EBIT VS OCF VS FCFVNDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

With an excellent Return On Assets value of -14.01%, VNDA belongs to the best of the industry, outperforming 80.83% of the companies in the same industry.
VNDA has a better Return On Equity (-18.07%) than 84.21% of its industry peers.
Industry RankSector Rank
ROA -14.01%
ROE -18.07%
ROIC N/A
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
VNDA Yearly ROA, ROE, ROICVNDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

Looking at the Gross Margin, with a value of 94.44%, VNDA belongs to the top of the industry, outperforming 95.11% of the companies in the same industry.
VNDA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for VNDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
VNDA Yearly Profit, Operating, Gross MarginsVNDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VNDA has been increased compared to 1 year ago.
Compared to 5 years ago, VNDA has more shares outstanding
VNDA has a worse debt/assets ratio than last year.
VNDA Yearly Shares OutstandingVNDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
VNDA Yearly Total Debt VS Total AssetsVNDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

VNDA has an Altman-Z score of 1.37. This is a bad value and indicates that VNDA is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.37, VNDA is doing good in the industry, outperforming 63.72% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that VNDA is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.01, VNDA perfoms like the industry average, outperforming 45.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 1.37
ROIC/WACCN/A
WACC8.77%
VNDA Yearly LT Debt VS Equity VS FCFVNDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 3.12 indicates that VNDA has no problem at all paying its short term obligations.
VNDA's Current ratio of 3.12 is on the low side compared to the rest of the industry. VNDA is outperformed by 63.35% of its industry peers.
A Quick Ratio of 3.10 indicates that VNDA has no problem at all paying its short term obligations.
VNDA's Quick ratio of 3.10 is on the low side compared to the rest of the industry. VNDA is outperformed by 60.90% of its industry peers.
Industry RankSector Rank
Current Ratio 3.12
Quick Ratio 3.1
VNDA Yearly Current Assets VS Current LiabilitesVNDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

2

3. Growth

3.1 Past

VNDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -407.14%.
Looking at the last year, VNDA shows a quite strong growth in Revenue. The Revenue has grown by 11.12% in the last year.
VNDA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.64% yearly.
EPS 1Y (TTM)-407.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-322.22%
Revenue 1Y (TTM)11.12%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%18.06%

3.2 Future

Based on estimates for the next years, VNDA will show a very negative growth in Earnings Per Share. The EPS will decrease by -46.02% on average per year.
Based on estimates for the next years, VNDA will show a small growth in Revenue. The Revenue will grow by 1.13% on average per year.
EPS Next Y-635.52%
EPS Next 2Y-121.38%
EPS Next 3Y-46.02%
EPS Next 5YN/A
Revenue Next Year9.44%
Revenue Next 2Y15.35%
Revenue Next 3Y18.27%
Revenue Next 5Y1.13%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VNDA Yearly Revenue VS EstimatesVNDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
VNDA Yearly EPS VS EstimatesVNDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VNDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VNDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VNDA Price Earnings VS Forward Price EarningsVNDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VNDA Per share dataVNDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

VNDA's earnings are expected to decrease with -46.02% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-121.38%
EPS Next 3Y-46.02%

More info and screens

0

5. Dividend

5.1 Amount

VNDA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

VANDA PHARMACEUTICALS INC

NASDAQ:VNDA (12/19/2025, 8:20:43 PM)

After market: 6.82 +0.07 (+1.04%)

6.75

+0.08 (+1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)02-11 2026-02-11/amc
Inst Owners78.67%
Inst Owner Change-0.28%
Ins Owners7.03%
Ins Owner Change0.2%
Market Cap398.93M
Revenue(TTM)212.07M
Net Income(TTM)-84.20M
Analysts80
Price Target11.99 (77.63%)
Short Float %8.46%
Short Ratio4.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.31%
Min EPS beat(2)-26.44%
Max EPS beat(2)17.82%
EPS beat(4)3
Avg EPS beat(4)8.92%
Min EPS beat(4)-26.44%
Max EPS beat(4)26.47%
EPS beat(8)6
Avg EPS beat(8)-4.56%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.83%
Min Revenue beat(2)-6.09%
Max Revenue beat(2)-5.56%
Revenue beat(4)1
Avg Revenue beat(4)-0.79%
Min Revenue beat(4)-6.09%
Max Revenue beat(4)8.7%
Revenue beat(8)3
Avg Revenue beat(8)1.4%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.24%
PT rev (3m)-7.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-146.79%
EPS NY rev (1m)-28.67%
EPS NY rev (3m)-27.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.6%
Revenue NY rev (1m)-2.02%
Revenue NY rev (3m)-2.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.88
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 1.12
EV/EBITDA N/A
EPS(TTM)-1.42
EYN/A
EPS(NY)-1.57
Fwd EYN/A
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS3.59
BVpS7.88
TBVpS6.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.01%
ROE -18.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.44%
FCFM N/A
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
F-Score3
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.83%
Cap/Sales 0.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.12
Quick Ratio 3.1
Altman-Z 1.37
F-Score3
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)14.89%
Cap/Depr(5y)25.49%
Cap/Sales(3y)0.24%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-407.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-322.22%
EPS Next Y-635.52%
EPS Next 2Y-121.38%
EPS Next 3Y-46.02%
EPS Next 5YN/A
Revenue 1Y (TTM)11.12%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%18.06%
Revenue Next Year9.44%
Revenue Next 2Y15.35%
Revenue Next 3Y18.27%
Revenue Next 5Y1.13%
EBIT growth 1Y-223.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-425.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-415.99%
OCF growth 3YN/A
OCF growth 5YN/A

VANDA PHARMACEUTICALS INC / VNDA FAQ

What is the ChartMill fundamental rating of VANDA PHARMACEUTICALS INC (VNDA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VNDA.


Can you provide the valuation status for VANDA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to VANDA PHARMACEUTICALS INC (VNDA). This can be considered as Overvalued.


What is the profitability of VNDA stock?

VANDA PHARMACEUTICALS INC (VNDA) has a profitability rating of 4 / 10.


What is the earnings growth outlook for VANDA PHARMACEUTICALS INC?

The Earnings per Share (EPS) of VANDA PHARMACEUTICALS INC (VNDA) is expected to decline by -635.52% in the next year.